» Articles » PMID: 1627406

The Impact of Cytotoxic Chemotherapy--perspectives from Patients, Specialists and Nurses

Overview
Journal Eur J Cancer
Specialty Oncology
Date 1992 Jan 1
PMID 1627406
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This study, carried out in three European countries, elicited the views and impact of three medical groups involved in patient care. Their views were compared with patients' perspectives of their condition. The main stage of the study was carried out by self-completion questionnaires by 300 patients across Italy, France and the U.K. The views of the medical profession were quantified via 150 hospital specialists, 75 cancer care nurses and 30 general practitioner interviews. Patients' symptoms most frequently seen by the medical profession were nausea, tiredness, loss of hair, vomiting, worrying and lack of appetite. On a scale of 1-4 (1 = not at all; 4 = very much) the frequency of these side effects were rated at 2.8 or over. Intensity of concern was highest for nausea and vomiting. These two symptoms was most frequently highlighted as one of the three highest concerns respectively for 74% and 54% of specialists, 64% and 60% of nurses and 50% of general practitioners. Patients on average reported a lower frequency of major symptoms. Most frequent were loss of hair, tiredness, lack of energy, nausea and decreased sexual interest. In terms of the impact of these problems, tiredness, nausea and loss of hair were the most frequently mentioned. Vomiting bothered them more than the frequency would suggest. 1 in 10 patients claim to have delayed their treatment because of previous experiences of side effects. The main impact on patient's quality of life related to the aspects of worrying and the effects on the family. In terms of communication, both the medical profession and the patients felt that patients were well informed about the disease and treatment. However, differences emerged between what patients claim to have been told about the disease and its treatment and what nurses and doctors claim to have said.

Citing Articles

Assessing the unmet needs of patients with advanced cancer treated by biological and precision therapies: protocol for TARGET, a mixed methods study.

Crowe L, Brown M, Bojke A, Bojke R, Greystoke A, Lecouturier J BMJ Open. 2023; 13(5):e066229.

PMID: 37142322 PMC: 10163501. DOI: 10.1136/bmjopen-2022-066229.


A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction.

Mosa A, Rana M, Islam H, Hossain A, Yoo I JMIR Mhealth Uhealth. 2021; 9(12):e27024.

PMID: 34860677 PMC: 8686466. DOI: 10.2196/27024.


Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.

Kim J, Baek J, Park S, Choi I, Kim S, Kim D Cancer Res Treat. 2010; 36(6):372-6.

PMID: 20368831 PMC: 2843880. DOI: 10.4143/crt.2004.36.6.372.


Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study.

Mandala M, Cremonesi M, Rocca A, Cazzaniga M, Ferretti G, Di Cosimo S Support Care Cancer. 2005; 13(6):375-80.

PMID: 15668754 DOI: 10.1007/s00520-004-0741-z.


Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care.

Viens P, Bouscary M, Genre D, Resbeut M, Gravis G, Camerlo J Br J Cancer. 1997; 76(12):1640-5.

PMID: 9413955 PMC: 2228193. DOI: 10.1038/bjc.1997.610.